Single-dose sodium polystyrene sulfonate for hyperkalemia in chronic kidney disease or end-stage renal disease
- PMID: 31198541
- PMCID: PMC6543963
- DOI: 10.1093/ckj/sfy063
Single-dose sodium polystyrene sulfonate for hyperkalemia in chronic kidney disease or end-stage renal disease
Abstract
Background: The use of sodium polystyrene sulfonate (SPS) for the treatment of hyperkalemia lacks sufficient efficacy data in patients with chronic kidney disease (CKD) and end-stage renal disease (ESRD); however, use remains widespread. Recent evidence suggests that this population may be at risk for serious gastrointestinal adverse effects with SPS. Methods. We conducted a single-center retrospective cohort study. Adult patients with CKD Stages 4, 5, or ESRD maintained on renal replacement therapy with serum potassium >5 mEq/L and receipt of SPS were screened for inclusion. Our primary outcome was decrease in potassium within 24 h post-30 g oral SPS suspended in 33% sorbitol. Secondary outcomes included decrease in potassium within 24 h from 15 or 30 g SPS doses and gastrointestinal adverse events.
Results: Of 596 records, 114 were included for analysis. At the first serum potassium level within 24 h post-30 g oral SPS the median potassium decrease was 0.8 mEq/L [interquartile range (IQR) 0.4-1.1; P < 0.001]. At the first potassium level within 24 h post-15 or 30 g SPS, the median potassium decrease was 0.7 mEq/L (IQR 0.4-1.0; P < 0.001]. Post-SPS potassium levels occurred 14-16 h post-SPS. Gastrointestinal side effects occurred within 30 days of SPS in 5% of patients, although only two cases were classified as possibly associated.
Conclusions: The use of single-dose SPS monotherapy resulted in a significant decrease in serum potassium levels within 24 h in patients with CKD Stage 4, 5, or ESRD. However, it remains unclear if SPS is associated with an increased risk of gastrointestinal injury in this population.
Keywords: chronic kidney disease; end-stage renal disease; hyperkalemia; sodium polystyrene sulfonate.
Figures


Similar articles
-
Polysulfonate Resins in Hyperkalemia: A Systematic Review.Can J Kidney Health Dis. 2020 Oct 30;7:2054358120965838. doi: 10.1177/2054358120965838. eCollection 2020. Can J Kidney Health Dis. 2020. PMID: 33240515 Free PMC article.
-
Evaluation of the tolerability and efficacy of sodium polystyrene sulfonate for long-term management of hyperkalemia in patients with chronic kidney disease.Int Urol Nephrol. 2017 Dec;49(12):2217-2221. doi: 10.1007/s11255-017-1717-5. Epub 2017 Oct 11. Int Urol Nephrol. 2017. PMID: 29027620
-
Comparison of effectiveness and safety of sodium polystyrene sulfonate and sodium zirconium cyclosilicate for treatment of hyperkalemia in hospitalized patients.Am J Health Syst Pharm. 2023 Sep 7;80(18):1238-1246. doi: 10.1093/ajhp/zxad137. Am J Health Syst Pharm. 2023. PMID: 37335862
-
Pharmacologic Treatment of Chronic Hyperkalemia in Patients with Chronic Kidney Disease.Electrolyte Blood Press. 2019 Jun;17(1):1-6. doi: 10.5049/EBP.2019.17.1.1. Epub 2019 Jun 30. Electrolyte Blood Press. 2019. PMID: 31338108 Free PMC article. Review.
-
An evaluation of sodium zirconium cyclosilicate as a treatment option for hyperkalemia.Expert Opin Pharmacother. 2021 Jan;22(1):19-28. doi: 10.1080/14656566.2020.1810234. Epub 2020 Sep 7. Expert Opin Pharmacother. 2021. PMID: 32892634 Review.
Cited by
-
Polysulfonate Resins in Hyperkalemia: A Systematic Review.Can J Kidney Health Dis. 2020 Oct 30;7:2054358120965838. doi: 10.1177/2054358120965838. eCollection 2020. Can J Kidney Health Dis. 2020. PMID: 33240515 Free PMC article.
-
Comparison of Patiromer to Sodium Polystyrene Sulfonate in Acute Hyperkalemia.Hosp Pharm. 2022 Jun;57(3):359-364. doi: 10.1177/00185787211037552. Epub 2021 Aug 5. Hosp Pharm. 2022. PMID: 35615481 Free PMC article.
-
Long-term safety and efficacy of sodium zirconium cyclosilicate for hyperkalaemia in patients with mild/moderate versus severe/end-stage chronic kidney disease: comparative results from an open-label, Phase 3 study.Nephrol Dial Transplant. 2021 Jan 1;36(1):137-150. doi: 10.1093/ndt/gfz285. Nephrol Dial Transplant. 2021. PMID: 32030422 Free PMC article. Clinical Trial.
-
Efficacy of orally administered montmorillonite in myoglobinuric acute renal failure model in male rats.Iran J Basic Med Sci. 2023;26(7):753-759. doi: 10.22038/IJBMS.2023.67985.14866. Iran J Basic Med Sci. 2023. PMID: 37396944 Free PMC article.
-
Treatment of Mild Hyperkalemia in Hospitalized Patients: An Unnecessary Practice?Can J Hosp Pharm. 2021 Summer;74(3):269-276. doi: 10.4212/cjhp.v74i3.3154. Epub 2021 Jul 1. Can J Hosp Pharm. 2021. PMID: 34248167 Free PMC article.
References
-
- Centers for Disease Control and Prevention. Chronic kidney disease surveillance system – United States. https://nccd.cdc.gov/ckd/ (4 April 2018, date last accessed)
-
- KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int Suppl 2013; 3: 91–111 - PubMed
-
- KDIGO clinical practice guideline for acute kidney injury. Kidney Int Suppl 2012; 2: 6
-
- Alfonzo A, Soar J, MacTier R. Clinical practice guidelines: treatment of acute hyperkalaemia in adults. UK Renal Association, 2014. https://renal.org/wp-content/uploads/2017/06/hyperkalaemia-guideline-1.pdf (10 August 2016, date last accessed)
LinkOut - more resources
Full Text Sources